Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal

Weiguo Li, Kimiko Ota, Jiro Nakamura, Keiko Naruse, Eitaro Nakashima, Yutaka Oiso, Yoji Hamada

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Gliclazide, a sulfonylurea widely used for treatment of diabetes mellitus, is known to scavenge reactive oxygen species. To clarify whether its antioxidative ability interferes with the glycation processes, we incubated bovine serum albumin (BSA) with 1 M glucose or 1 mM methylglyoxal, in the presence or absence of gliclazide, and observed the formation of advanced glycation end products (AGEs). AGE production was assessed by AGE-specific fluorescence, an enzyme-linked immunosorbent assay (ELISA), and Western blotting. The fluorescence at excitation/emission wavelengths of 320/383 nm and 335/385 nm was definitely increased by incubating BSA with 1 M glucose or 1 mM methylglyoxal, and 1 mM gliclazide significantly blunted the fluorescent augmentation, in both wavelengths, in a dose-dependent fashion. Gliclazide almost equaled to aminoguanidine, a putative antiglycation agent, in the inhibitory effect on the glucose-induced fluorescence, while the methylglyoxal-derived fluorescent formation was less suppressed by gliclazide than by aminoguanidine. The AGE concentrations determined by ELISA showed similar results. Incubation of BSA with 1 M glucose or 1 mM methylglyoxal yielded an apparent increase in carboxymethyllysine or argpyrimidine. Both AGEs were significantly lowered by 1 mM gliclazide and a reduction of glucose-derived carboxymethyllysine was comparable to that caused by amino-guanidine. The results of Western blotting supported the findings in ELISA. To our knowledge, the present study provides the first evidence of the antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal.

Original languageEnglish (US)
Pages (from-to)176-179
Number of pages4
JournalExperimental Biology and Medicine
Volume233
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Gliclazide
Pyruvaldehyde
Glucose
Immunosorbents
Bovine Serum Albumin
Assays
Fluorescence
Enzyme-Linked Immunosorbent Assay
Enzymes
Western Blotting
Wavelength
Advanced Glycosylation End Products
Guanidine
Medical problems
In Vitro Techniques
Dosimetry
Reactive Oxygen Species
Diabetes Mellitus

Keywords

  • Advanced glycation end products
  • Gliclazide
  • Glycation
  • Oxidative stress

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Li, W., Ota, K., Nakamura, J., Naruse, K., Nakashima, E., Oiso, Y., & Hamada, Y. (2008). Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal. Experimental Biology and Medicine, 233(2), 176-179. https://doi.org/10.3181/0705-BC-131

Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal. / Li, Weiguo; Ota, Kimiko; Nakamura, Jiro; Naruse, Keiko; Nakashima, Eitaro; Oiso, Yutaka; Hamada, Yoji.

In: Experimental Biology and Medicine, Vol. 233, No. 2, 01.02.2008, p. 176-179.

Research output: Contribution to journalArticle

Li, W, Ota, K, Nakamura, J, Naruse, K, Nakashima, E, Oiso, Y & Hamada, Y 2008, 'Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal', Experimental Biology and Medicine, vol. 233, no. 2, pp. 176-179. https://doi.org/10.3181/0705-BC-131
Li, Weiguo ; Ota, Kimiko ; Nakamura, Jiro ; Naruse, Keiko ; Nakashima, Eitaro ; Oiso, Yutaka ; Hamada, Yoji. / Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal. In: Experimental Biology and Medicine. 2008 ; Vol. 233, No. 2. pp. 176-179.
@article{b74d7331291a4dd6a2617a37f14e4d84,
title = "Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal",
abstract = "Gliclazide, a sulfonylurea widely used for treatment of diabetes mellitus, is known to scavenge reactive oxygen species. To clarify whether its antioxidative ability interferes with the glycation processes, we incubated bovine serum albumin (BSA) with 1 M glucose or 1 mM methylglyoxal, in the presence or absence of gliclazide, and observed the formation of advanced glycation end products (AGEs). AGE production was assessed by AGE-specific fluorescence, an enzyme-linked immunosorbent assay (ELISA), and Western blotting. The fluorescence at excitation/emission wavelengths of 320/383 nm and 335/385 nm was definitely increased by incubating BSA with 1 M glucose or 1 mM methylglyoxal, and 1 mM gliclazide significantly blunted the fluorescent augmentation, in both wavelengths, in a dose-dependent fashion. Gliclazide almost equaled to aminoguanidine, a putative antiglycation agent, in the inhibitory effect on the glucose-induced fluorescence, while the methylglyoxal-derived fluorescent formation was less suppressed by gliclazide than by aminoguanidine. The AGE concentrations determined by ELISA showed similar results. Incubation of BSA with 1 M glucose or 1 mM methylglyoxal yielded an apparent increase in carboxymethyllysine or argpyrimidine. Both AGEs were significantly lowered by 1 mM gliclazide and a reduction of glucose-derived carboxymethyllysine was comparable to that caused by amino-guanidine. The results of Western blotting supported the findings in ELISA. To our knowledge, the present study provides the first evidence of the antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal.",
keywords = "Advanced glycation end products, Gliclazide, Glycation, Oxidative stress",
author = "Weiguo Li and Kimiko Ota and Jiro Nakamura and Keiko Naruse and Eitaro Nakashima and Yutaka Oiso and Yoji Hamada",
year = "2008",
month = "2",
day = "1",
doi = "10.3181/0705-BC-131",
language = "English (US)",
volume = "233",
pages = "176--179",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "1535-3702",
publisher = "Society for Experimental Biology and Medicine",
number = "2",

}

TY - JOUR

T1 - Antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal

AU - Li, Weiguo

AU - Ota, Kimiko

AU - Nakamura, Jiro

AU - Naruse, Keiko

AU - Nakashima, Eitaro

AU - Oiso, Yutaka

AU - Hamada, Yoji

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Gliclazide, a sulfonylurea widely used for treatment of diabetes mellitus, is known to scavenge reactive oxygen species. To clarify whether its antioxidative ability interferes with the glycation processes, we incubated bovine serum albumin (BSA) with 1 M glucose or 1 mM methylglyoxal, in the presence or absence of gliclazide, and observed the formation of advanced glycation end products (AGEs). AGE production was assessed by AGE-specific fluorescence, an enzyme-linked immunosorbent assay (ELISA), and Western blotting. The fluorescence at excitation/emission wavelengths of 320/383 nm and 335/385 nm was definitely increased by incubating BSA with 1 M glucose or 1 mM methylglyoxal, and 1 mM gliclazide significantly blunted the fluorescent augmentation, in both wavelengths, in a dose-dependent fashion. Gliclazide almost equaled to aminoguanidine, a putative antiglycation agent, in the inhibitory effect on the glucose-induced fluorescence, while the methylglyoxal-derived fluorescent formation was less suppressed by gliclazide than by aminoguanidine. The AGE concentrations determined by ELISA showed similar results. Incubation of BSA with 1 M glucose or 1 mM methylglyoxal yielded an apparent increase in carboxymethyllysine or argpyrimidine. Both AGEs were significantly lowered by 1 mM gliclazide and a reduction of glucose-derived carboxymethyllysine was comparable to that caused by amino-guanidine. The results of Western blotting supported the findings in ELISA. To our knowledge, the present study provides the first evidence of the antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal.

AB - Gliclazide, a sulfonylurea widely used for treatment of diabetes mellitus, is known to scavenge reactive oxygen species. To clarify whether its antioxidative ability interferes with the glycation processes, we incubated bovine serum albumin (BSA) with 1 M glucose or 1 mM methylglyoxal, in the presence or absence of gliclazide, and observed the formation of advanced glycation end products (AGEs). AGE production was assessed by AGE-specific fluorescence, an enzyme-linked immunosorbent assay (ELISA), and Western blotting. The fluorescence at excitation/emission wavelengths of 320/383 nm and 335/385 nm was definitely increased by incubating BSA with 1 M glucose or 1 mM methylglyoxal, and 1 mM gliclazide significantly blunted the fluorescent augmentation, in both wavelengths, in a dose-dependent fashion. Gliclazide almost equaled to aminoguanidine, a putative antiglycation agent, in the inhibitory effect on the glucose-induced fluorescence, while the methylglyoxal-derived fluorescent formation was less suppressed by gliclazide than by aminoguanidine. The AGE concentrations determined by ELISA showed similar results. Incubation of BSA with 1 M glucose or 1 mM methylglyoxal yielded an apparent increase in carboxymethyllysine or argpyrimidine. Both AGEs were significantly lowered by 1 mM gliclazide and a reduction of glucose-derived carboxymethyllysine was comparable to that caused by amino-guanidine. The results of Western blotting supported the findings in ELISA. To our knowledge, the present study provides the first evidence of the antiglycation effect of gliclazide on in vitro AGE formation from glucose and methylglyoxal.

KW - Advanced glycation end products

KW - Gliclazide

KW - Glycation

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=38949212996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949212996&partnerID=8YFLogxK

U2 - 10.3181/0705-BC-131

DO - 10.3181/0705-BC-131

M3 - Article

C2 - 18222972

AN - SCOPUS:38949212996

VL - 233

SP - 176

EP - 179

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 1535-3702

IS - 2

ER -